01
Overview
Biocodex markets the world’s leading probiotic yeast drug Saccharomyces boulardii CNCM I‑745®, with extensive clinical validation for gastrointestinal health. Its orphan drug Diacomit® (stiripentol) is approved internationally for Dravet syndrome. The company continues to invest in R&D across microbiota care, women’s health, and rare diseases. Early-stage research suggests potential new uses of Diacomit® in oncology settings[8][6][10].
- Therapeutic areas
- GastroenterologyOncologyNeurologyWomen's Health
- Modalities
- Probiotics (notably Saccharomyces boulardii CNCM I-745®)Small molecules (e.g., stiripentol/Diacomit®)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Kinnov Therapeutics
Beyond the preview
Go deeper on Biocodex.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biocodex.